Horizon Pharma Public Limited Company (HZNP)
(Delayed Data from NSDQ)
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Ascendis' Dwarfism Candidate Gets Orphan Drug Status in EU
by Zacks Equity Research
Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.
Roche's Xolair sBLA for Self Administration Accepted by FDA
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) sBLA for a new self-administration option for Xolair across all approved U.S. indications.
Axsome's (AXSM) Earnings Beat in Q2, Pipeline Progresses
by Zacks Equity Research
Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.
Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts
by Zacks Equity Research
Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.
Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.
AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates
by Zacks Equity Research
AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.
Top Ranked Momentum Stocks to Buy for August 11th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 11th
Biohaven (BHVN) Q2 Earnings Beat on Strong Nurtec Uptake
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.
Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.
Horizon Therapeutics (HZNP) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Horizon Therapeutics (HZNP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.
Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact
by Zacks Equity Research
Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.
ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales
by Zacks Equity Research
ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.
Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales
by Zacks Equity Research
Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.
Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the second quarter of 2020.
Sarepta (SRPT) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q2 revenues increase year over year.
Arena Pharmaceuticals (ARNA) Q2 Loss Narrower Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
BioDelivery (BDSI) Q2 Earnings Miss, Revenues Beat, Stock Up
by Zacks Equity Research
BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. Stock up.
Jazz Pharma (JAZZ) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020. Shares rise.
BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact
by Zacks Equity Research
BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.
Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe
by Zacks Equity Research
Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.
Horizon Therapeutics (HZNP) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 7.50% and 26.67%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More
by Kinjel Shah
Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.
BMY vs. HZNP: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. HZNP: Which Stock Is the Better Value Option?
Horizon Therapeutics (HZNP) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Horizon Therapeutics (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.